FIGURE 3.

Survival outcomes for patients with HRAS-mutant, advanced salivary gland cancer who were treated with tipifarnib based on molecular findings. Kaplan-Meier survival curves showing (A) overall survival (OS) measured in months from the time of the initial diagnosis of salivary gland cancer to death or else censored at the time of last known follow-up for those subjects with a Q61R HRAS variant (7 patients) versus other gene variants in HRAS (6 patients) and (B) OS measured in months from the time of initiation of tipifarnib dosing to death or else censored at the time of last known follow-up between HRAS/PIK3CA co-mutated (mut) or coamplified (amp) subjects (8 patients vs 5 patients without co-mutation or coamplification). The number of subjects at risk is shown below each curve. HR indicates hazard ratio. *P < .05 using the log-rank test.